Cargando…

Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy

This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanced solid tumors. Oral dose escalation was investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schneeweiss, Andreas, Hess, Dagmar, Joerger, Markus, Varga, Andrea, Moulder, Stacy, Tsimberidou, Apostolia M., Ma, Cynthia, Hurvitz, Sara A., Rentzsch, Christine, Rudolph, Marion, Thiele, Silke, Boix, Oliver, Wilkinson, Gary, Lagkadinou, Eleni, Ocker, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966663/ https://www.ncbi.nlm.nih.gov/pubmed/31835495 http://dx.doi.org/10.3390/cancers11121987

Ejemplares similares

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
por: Yu, Yi, et al.
Publicado: (2015)

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
por: Wheler, Jennifer J., et al.
Publicado: (2014)

Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
por: Quambusch, Lena, et al.
Publicado: (2019)

Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin
por: Pant, Alok, et al.
Publicado: (2012)

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing
por: Janku, Filip, et al.
Publicado: (2014)

Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt
por: Uhlenbrock, Niklas, et al.
Publicado: (2019)

AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2022)

Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors
por: Savill, Kristin M. Zimmerman, et al.
Publicado: (2022)

Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment Approach
por: van der Westhuizen, Leandi, et al.
Publicado: (2022)

All Akt Isoforms (Akt1, Akt2, Akt3) Are Involved in Normal Hearing, but Only Akt2 and Akt3 Are Involved in Auditory Hair Cell Survival in the Mammalian Inner Ear
por: Brand, Yves, et al.
Publicado: (2015)

Search of Allosteric Inhibitors and Associated Proteins of an AKT-like Kinase from Trypanosoma cruzi
por: Ochoa, Rodrigo, et al.
Publicado: (2018)

Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells
por: Bougen-Zhukov, Nicola, et al.
Publicado: (2019)

Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development
por: Page, Natalie, et al.
Publicado: (2022)

Akt Is S-Palmitoylated: A New Layer of Regulation for Akt
por: Blaustein, Matías, et al.
Publicado: (2021)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience
por: Hou, Ming-Mo, et al.
Publicado: (2014)

Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients
por: Le Page, C, et al.
Publicado: (2006)

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
por: Zhao, Yuan-Yuan, et al.
Publicado: (2014)

Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt
por: Huang, Bill X., et al.
Publicado: (2017)

Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancer
por: Baby, Krishnaprasad, et al.
Publicado: (2023)

Akt destabilizes p57(Kip2): Akt at the converging crossroad?
por: Lo, Hui-Wen
Publicado: (2013)

AKT2 is the predominant AKT isoform expressed in human skeletal muscle
por: Matheny, Ronald W., et al.
Publicado: (2018)

Brown fat organogenesis and maintenance requires AKT1 and AKT2
por: Sanchez-Gurmaches, Joan, et al.
Publicado: (2019)

Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
por: Wu, Wen-I, et al.
Publicado: (2010)

Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities
por: Hubbard, Paul A., et al.
Publicado: (2014)

Targeting allosteric site of AKT by 5,7-dimethoxy-1,4-phenanthrenequinone suppresses neutrophilic inflammation
por: Chen, Po-Jen, et al.
Publicado: (2019)

Akt in the pathogenesis of COPD
por: Bozinovski, Steven, et al.
Publicado: (2006)

Akt-Girdin as oncotarget
por: Takahashi, Masahide, et al.
Publicado: (2015)

Drosophila eugracilis – Akt
por: Morgan, Ashley, et al.
Publicado: (2022)

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2021)

Getting the Akt Together: Guiding Intracellular Akt Activity by PI3K
por: Yudushkin, Ivan
Publicado: (2019)

Akt methylation by SETDB1 promotes Akt kinase activity and oncogenic functions
por: Guo, Jianping, et al.
Publicado: (2019)

What Does the “AKT” Stand for in the Name “AKT Kinase”? Some Historical Comments
por: Xie, Jiuyong, et al.
Publicado: (2020)

HijAkt: The PI3K/Akt Pathway in Virus Replication and Pathogenesis
por: Dunn, Ewan F., et al.
Publicado: (2012)

The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane
por: Berndt, Norbert, et al.
Publicado: (2010)

Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
por: Lee, Jii Bum, et al.
Publicado: (2021)

Role of a Novel PH-Kinase Domain Interface in PKB/Akt Regulation: Structural Mechanism for Allosteric Inhibition
por: Calleja, Véronique, et al.
Publicado: (2009)

The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures
por: Narayan, Ravi S., et al.
Publicado: (2017)

Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis
por: Franks, S. Elizabeth, et al.
Publicado: (2015)

Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation
por: Nogueira, Veronique, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2j15sjgm4lke0hrqimo1a6b8sr